Johanne Martel-Pelletier

List of Publications by Year
in descending order

217 papers	17,701 citations	11651 70 h-index	14759 127 g-index
272 all docs	272 docs citations	272 times ranked	13319 citing authors

#	Article	IF	Citations
1	The relationship between knee loading during gait and cartilage thickness in nontraumatic and posttraumatic knee osteoarthritis. Journal of Orthopaedic Research, 2022, 40, 1778-1786.	2.3	2
2	An Open Debate on the Morphological Measurement Methodologies of the Infrapatellar Fat Pad to Determine Its Association with the Osteoarthritis Process. Current Rheumatology Reports, 2022, 24, 76-80.	4.7	2
3	Estrogenic impregnation alters pain expression: analysis through functional neuropeptidomics in a surgical rat model of osteoarthritis. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 703-715.	3.0	4
4	Risk factors associated with the occurrence of total knee arthroplasty in patients with knee osteoarthritis: a nested caseâ€“control study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210913.	2.7	1
5	Vastus medialis intramuscular fat is associated with reduced quadriceps strength, but not knee osteoarthritis severity. Clinical Biomechanics, 2022, 96, 105669.	1.2	2
6	Mass spectrometry-based proteomics identify novel serum osteoarthritis biomarkers. Arthritis Research and Therapy, 2022, 24, .	3.5	17
7	A Machine Learning Model to Predict Knee Osteoarthritis Cartilage Volume Changes over Time Using Baseline Bone Curvature. Biomedicines, 2022, 10, 1247.	3.2	8
8	The association between change in bone marrow lesion size and change in tibiofemoral cartilage volume and knee symptoms. Rheumatology, 2021, 60, 2791-2800.	1.9	9
9	A warning machine learning algorithm for early knee osteoarthritis structural progressor patient screening. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2199325.	2.7	24
10	Associations of blood pressure and arterial stiffness with knee cartilage volume in patients with knee osteoarthritis. Rheumatology, 2021, 60, 4748-4754.	1.9	2
11	Machine Learningâ€“Based Individualized Survival Prediction Model for Total Knee Replacement in Osteoarthritis: Data From the Osteoarthritis Initiative. Arthritis Care and Research, 2021, 73, 1518-1527.	3.4	21
12	Common Biochemical and Magnetic Resonance Imaging Biomarkers of Early Knee Osteoarthritis and of Exercise/Training in Athletes: A Narrative Review. Diagnostics, 2021, 11, 1488.	2.6	4
13	Clinical relevance of MRI knee abnormalities in Australian rules football players: a longitudinal study. BMJ Open Sport and Exercise Medicine, 2021, 7, e001097.	2.9	0
14	Associations of Joint Line Tenderness and Patellofemoral Grind With Longâ€Term Knee Joint Outcomes: Data From the Osteoarthritis Initiative. Arthritis Care and Research, 2020, 72, 778-786.	3.4	3
15	Mesenchymal Stromal Cell Immunology for Efficient and Safe Treatment of Osteoarthritis. Frontiers in Cell and Developmental Biology, 2020, 8, 567813.	3.7	21
16	Intra-articular corticosteroid knee injection induces a reduction in meniscal thickness with no treatment effect on cartilage volume: a caseâ€“control study. Scientific Reports, 2020, 10, 13789.	3.3	16
17	Identification of the most important features of knee osteoarthritis structural progressors using machine learning methods. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093346.	2.7	25
18	A continuous data driven translational model to evaluate effectiveness of population-level health interventions: case study, smoking ban in public places on hospital admissions for acute coronary events. Journal of Translational Medicine, 2020, 18, 466.	4.4	4

#	Article	IF	Citations
19	Serum adipokines/related inflammatory factors and ratios as predictors of infrapatellar fat pad volume in osteoarthritis: Applying comprehensive machine learning approaches. Scientific Reports, 2020, 10, 9993.	3.3	13
20	An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. Rheumatology, 2020, 59, 3858-3868.	1.9	26
21	A reliable time-series method for predicting arthritic disease outcomes: New step from regression toward a nonlinear artificial intelligence method. Computer Methods and Programs in Biomedicine, 2020, 189, 105315.	4.7	12
22	Role of Lipocalinâ€Type Prostaglandin D Synthase in Experimental Osteoarthritis. Arthritis and Rheumatology, 2020, 72, 1524-1533.	5.6	8
23	Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions. JAMA - Journal of the American Medical Association, 2020, 323, 1456.	7.4	59
24	Viewpoint on Time Series and Interrupted Time Series Optimum Modeling for Predicting Arthritic Disease Outcomes. Current Rheumatology Reports, 2020, 22, 27.	4.7	3
25	In vivo protective effect of adipsin-deficiency on spontaneous knee osteoarthritis in aging mice. Aging, 2020, 12, 2880-2896.	3.1	8
26	Novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells. World Journal of Stem Cells, 2020, 12, 1474-1491.	2.8	9
27	L-PGDS deficiency accelerated the development of naturally occurring age-related osteoarthritis. Aging, 2020, 12, 24778-24797.	3.1	7
28	Activation of The Phosphatidylcholine to Lysophosphatidylcholine Pathway Is Associated with Osteoarthritis Knee Cartilage Volume Loss Over Time. Scientific Reports, 2019, 9, 9648.	3.3	34
29	Serum lysophosphatidylcholines to phosphatidylcholines ratio is associated with symptomatic responders to symptomatic drugs in knee osteoarthritis patients. Arthritis Research and Therapy, 2019, 21, 224.	3.5	13
30	An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 2019, 49, 337-350.	3.4	392
31	A new decision tree for diagnosis of osteoarthritis in primary care: international consensus of experts. Aging Clinical and Experimental Research, 2019, 31, 19-30.	2.9	31
32	Machine-learning-based patient-specific prediction models for knee osteoarthritis. Nature Reviews Rheumatology, 2019, 15, 49-60.	8.0	119
33	Osteoarthritic pain model influences functional outcomes and spinal neuropeptidomics: A pilot study in female rats. Canadian Journal of Veterinary Research, 2019, 83, 133-141.	0.2	4
34	Diacerein-containing products: same risk of diarrhoea?. Aging Clinical and Experimental Research, 2018, 30, 411-412.	2.9	12
35	In vivo effect of opticin deficiency in cartilage in a surgically induced mouse model of osteoarthritis. Scientific Reports, 2018, 8, 457.	3.3	8
36	How Do MRI-Detected Subchondral Bone Marrow Lesions (BMLs) on Two Different MRI Sequences Correlate with Clinically Important Outcomes?. Calcified Tissue International, 2018, 103, 131-143.	3.1	3

#	Article	IF	Citations
37	Validity of Combining History Elements and Physical Examination Tests to Diagnose Patellofemoral Pain. Archives of Physical Medicine and Rehabilitation, 2018, 99, 607-614.e1.	0.9	15
38	Exploring determinants predicting response to intra-articular hyaluronic acid treatment in symptomatic knee osteoarthritis: 9-year follow-up data from the Osteoarthritis Initiative. Arthritis Research and Therapy, 2018, 20, 40.	3.5	18
39	Reply. Arthritis Care and Research, 2018, 70, 168-168.	3.4	1
40	Refinement of the Montreal Instrument for Cat Arthritis Testing, for Use by Veterinarians: detection of naturally occurring osteoarthritis in laboratory cats. Journal of Feline Medicine and Surgery, 2018, 20, 728-740.	1.6	17
41	Diagnostic Validity of Combining History Elements and Physical Examination Tests for Traumatic and Degenerative Symptomatic Meniscal Tears. PM and R, 2018, 10, 472-482.	1.6	5
42	Knee pain as a predictor of structural progression over 4 years: data from the Osteoarthritis Initiative, a prospective cohort study. Arthritis Research and Therapy, 2018, 20, 250.	3.5	36
43	Initial derivation of diagnostic clusters combining history elements and physical examination tests for symptomatic knee osteoarthritis. Musculoskeletal Care, 2018, 16, 370-379.	1.4	2
44	High in vivo levels of adipsin lead to increased knee tissue degradation in osteoarthritis: data from humans and animal models. Rheumatology, 2018, 57, 1851-1860.	1.9	17
45	Impact of oral osteoarthritis therapyÂusage among other risk factors on knee replacement: a nested case-control study using the Osteoarthritis Initiative cohort. Arthritis Research and Therapy, 2018, 20, 172.	3.5	16
46	Clinical diagnosis of partial or complete anterior cruciate ligament tears using patients' history elements and physical examination tests. PLoS ONE, 2018, 13, e0198797.	2.5	19
47	Spinal neuropeptide modulation, functional assessment and cartilage lesions in a monosodium iodoacetate rat model of osteoarthritis. Neuropeptides, 2017, 65, 56-62.	2.2	12
48	Bone curvature changes can predict the impact of treatment on cartilage volume loss in knee osteoarthritis: data from a 2-year clinical trial. Rheumatology, 2017, 56, 989-998.	1.9	11
49	Exacerbation of Agingâ€Associated and Instabilityâ€Induced Murine Osteoarthritis With Deletion of D Prostanoid Receptor 1, a Prostaglandin D₂ Receptor. Arthritis and Rheumatology, 2017, 69, 1784-1795.	5.6	11
50	Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study. Arthritis Research and Therapy, 2017, 19, 169.	3.5	30
51	Analgesic efficacy of tramadol in cats with naturally occurring osteoarthritis. PLoS ONE, 2017, 12, e0175565.	2.5	35
52	The unfolded protein response genes in human osteoarthritic chondrocytes: PERK emerges as a potential therapeutic target. Arthritis Research and Therapy, 2016, 18, 172.	3.5	38
53	Analgesic efficacy of an oral transmucosal spray formulation of meloxicam alone or in combination with tramadol in cats with naturally occurring osteoarthritis. Veterinary Anaesthesia and Analgesia, 2016, 43, 643-651.	0.6	34
54	Longâ€Term Effects of Glucosamine and Chondroitin Sulfate on the Progression of Structural Changes in Knee Osteoarthritis: Sixâ€Year Followup Data From the Osteoarthritis Initiative. Arthritis Care and Research, 2016, 68, 1560-1566.	3.4	30

#	Article	IF	Citations
55	Correlation Between Changes in Global Knee Structures Assessed by Magnetic Resonance Imaging and Radiographic Osteoarthritis Changes Over Ten Years in a Midlife Cohort. Arthritis Care and Research, 2016, 68, 958-964.	3.4	7
56	Measuring Disease Progression in Osteoarthritis. Current Treatment Options in Rheumatology, 2016, 2, 97-110.	1.4	10
57	Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Research and Therapy, 2016, 18, 256.	3.5	38
58	Osteoarthritis. Nature Reviews Disease Primers, 2016, 2, 16072.	30.5	1,011
59	Does cartilage volume measurement or radiographic osteoarthritis at baseline independently predict ten-year cartilage volume loss?. BMC Musculoskeletal Disorders, 2016, 17, 54.	1.9	6
60	Natural history and clinical significance of meniscal tears over 8Âyears in a midlife cohort. BMC Musculoskeletal Disorders, 2016, 17, 4.	1.9	20
61	Change in knee structure and change in tibiofemoral joint space width: a five year longitudinal populationâ€“based study. BMC Musculoskeletal Disorders, 2016, 17, 25.	1.9	9
62	Cartilage-specific deletion of ephrin-B2 in mice results in early developmental defects and an osteoarthritis-like phenotype during aging in vivo. Arthritis Research and Therapy, 2016, 18, 65.	3.5	9
63	Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Annals of the Rheumatic Diseases, 2016, 75, 37-44.	0.9	194
64	Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Seminars in Arthritis and Rheumatism, 2016, 45, S22-S27.	3.4	101
65	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs and Aging, 2016, 33, 75-85.	2.7	116
66	A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritisâ€”From evidence-based medicine to the real-life setting. Seminars in Arthritis and Rheumatism, 2016, 45, S3-S11.	3.4	203
67	The levels of the adipokines adipsin and leptin are associated with knee osteoarthritis progression as assessed by MRI and incidence of total knee replacement in symptomatic osteoarthritis patients: apost hocanalysis. Rheumatology, 2016, 55, 680-688.	1.9	51
68	Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Seminars in Arthritis and Rheumatism, 2016, 45, S18-S21.	3.4	157
69	Animal models of osteoarthritis. , 2015, , 1454-1461.		4
70	Magnetic Resonance Imagingâ€“Assessed Vastus Medialis Muscle Fat Content and Risk for Knee Osteoarthritis Progression: Relevance From a Clinical Trial. Arthritis Care and Research, 2015, 67, 1406-1415.	3.4	26
71	Discrepancies in Composition and Biological Effects of Different Formulations of Chondroitin Sulfate. Molecules, 2015, 20, 4277-4289.	3.8	84
72	Meniscal extrusion promotes knee osteoarthritis structural progression: protective effect of strontium ranelate treatment in a phase III clinical trial. Arthritis Research and Therapy, 2015, 17, 82.	3.5	25

#	Article	IF	Citations
73	PPARÎ³ deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage. Annals of the Rheumatic Diseases, 2015, 74, 569-578.	0.9	186
74	The inÂVivo Effect of Prophylactic Subchondral Bone Protection of Osteoarthritic Synovial Membrane in Bone-Specific Ephb4-Overexpressing Mice. American Journal of Pathology, 2015, 185, 335-346.	3.8	8
75	Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Annals of the Rheumatic Diseases, 2015, 74, 422-429.	0.9	106
76	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. Drugs and Aging, 2015, 32, 525-535.	2.7	31
77	Impact of disease treatments on the progression of knee osteoarthritis structural changes related to meniscal extrusion: Data from the OAI progression cohort. Seminars in Arthritis and Rheumatism, 2015, 45, 257-267.	3.4	21
78	[18F]-fluorodeoxyglucose positron emission tomography of the cat brain: A feasibility study to investigate osteoarthritis-associated pain. Veterinary Journal, 2015, 204, 299-303.	1.7	19
79	Drug/Agent Treatments for Osteoarthritis: Present and Future. , 2015, , 191-210.		3
80	Coxofemoral joint kinematics using video fluoroscopic images of treadmill-walking cats: development of a technique to assess osteoarthritis-associated disability. Journal of Feline Medicine and Surgery, 2015, 17, 134-143.	1.6	4
81	Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis. Annals of the Rheumatic Diseases, 2015, 74, 1432-1440.	0.9	322
82	First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24â€…months: data from the osteoarthritis initiative progression cohort. Annals of the Rheumatic Diseases, 2015, 74, 547-556.	0.9	81
83	The longitudinal relationship between changes in body weight and changes in medial tibial cartilage, and pain among community-based adults with and without meniscal tears. Annals of the Rheumatic Diseases, 2014, 73, 1652-1658.	0.9	28
84	The presence of meniscal lesions is a strong predictor of neuropathic pain in symptomatic knee osteoarthritis: a cross-sectional pilot study. Arthritis Research and Therapy, 2014, 16, 507.	3.5	50
85	Responsiveness of Magnetic Resonance Imaging-derived Measures Over 2.7 Years. Journal of Rheumatology, 2014, 41, 2060-2067.	2.0	8
86	Characterization of opticin digestion by proteases involved in osteoarthritis development. Joint Bone Spine, 2014, 81, 137-141.	1.6	16
87	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014, 44, 253-263.	3.4	414
88	Evoked Temporal Summation in Cats to Highlight Central Sensitization Related to Osteoarthritis-Associated Chronic Pain: A Preliminary Study. PLoS ONE, 2014, 9, e97347.	2.5	26
89	New and emerging treatments for osteoarthritis management: will the dream come true with personalized medicine?. Expert Opinion on Pharmacotherapy, 2013, 14, 2059-2077.	1.8	24
90	NFAT3 and TGF-Î²/SMAD3 regulate the expression of miR-140 in osteoarthritis. Arthritis Research and Therapy, 2013, 15, R197.	3.5	62

#	Article	IF	Citations
91	Total Knee Replacement as a Knee Osteoarthritis Outcome. Cartilage, 2013, 4, 219-226.	2.7	29
92	Adult Cartilage-Specific Peroxisome Proliferatorâ€“Activated Receptor Gamma Knockout Mice Exhibit the Spontaneous Osteoarthritis Phenotype. American Journal of Pathology, 2013, 182, 1099-1106.	3.8	63
93	Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL-1Î² in the synovium. Annals of the Rheumatic Diseases, 2013, 72, 250-257.	0.9	68
94	Assessment of Cartilage Changes Over Time in Knee Osteoarthritis Diseaseâ€Modifying Osteoarthritis Drug Trials Using Semiquantitative and Quantitative Methods: Pros and Cons. Arthritis Care and Research, 2013, 65, 686-694.	3.4	24
95	Expression of Peroxisome Proliferator-activated Receptors Î±, Î², Î³, and H- and L-Prostaglandin D Synthase During Osteoarthritis in the Spontaneous Hartley Guinea Pig and Experimental Dog Models. Journal of Rheumatology, 2013, 40, 877-890.	2.0	17
96	Reliability and sensitivity to change of IW-TSE versus DESS magnetic resonance imaging sequences in the assessment of bone marrow lesions in knee osteoarthritis patients: Longitudinal data from the Osteoarthritis Initiative (OAI) cohort. Journal of Biomedical Science and Engineering, 2013, 06, 337-345.	0.4	5
97	Brachystemma calycinumD. Don Effectively Reduces the Locomotor Disability in Dogs with Naturally Occurring Osteoarthritis: A Randomized Placebo-Controlled Trial. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-9.	1.2	12
98	Influence of Tumor Necrosis Factor Î±, Parathyroid Hormone, and Vitamin D₃ on Modulation of the RANKL2 Isoform. Cartilage, 2012, 3, 100-103.	2.7	1
99	In vivo boneâ€specific EphB4 overexpression in mice protects both subchondral bone and cartilage during osteoarthritis. Arthritis and Rheumatism, 2012, 64, 3614-3625.	6.7	31
100	Future therapeutics for osteoarthritis. Bone, 2012, 51, 297-311.	2.9	93
101	A fully automated system for quantification of knee bone marrow lesions using MRI and the osteoarthritis initiative cohort. Journal of Biomedical Graphics and Computing, 2012, 3, .	0.2	6
102	Association of cartilageâ€specific deletion of peroxisome proliferatorâ€“activated receptor Î³ with abnormal endochondral ossification and impaired cartilage growth and development in a murine model. Arthritis and Rheumatism, 2012, 64, 1551-1561.	6.7	53
103	Egrâ€1 mediates the suppressive effect of ILâ€1 on PPARg expression in human OA chondrocytes. FASEB Journal, 2012, 26, lb80.	0.5	0
104	Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation. Annals of the Rheumatic Diseases, 2011, 70, 1382-1388.	0.9	93
105	Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nature Reviews Rheumatology, 2011, 7, 33-42.	8.0	1,973
106	Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone, 2011, 49, 559-567.	2.9	103
107	A fully automated human knee 3D MRI bone segmentation using the ray casting technique. Medical and Biological Engineering and Computing, 2011, 49, 1413-1424.	2.8	49
108	Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Annals of the Rheumatic Diseases, 2011, 70, 982-989.	0.9	164

#	Article	IF	Citations
109	Proteinase-activated Receptor-2 Gene Disruption Limits the Effect of Osteoarthritis on Cartilage in Mice: A Novel Target in Joint Degradation. Journal of Rheumatology, 2011, 38, 911-920.	2.0	30
110	Valproic acid suppresses interleukinâ€1Î²â€induced microsomal prostaglandin E2 Synthaseâ€1 expression in chondrocytes. FASEB Journal, 2011, 25, 945.14.	0.5	0
111	Prostaglandin D2 enhances interleukin â€1Î²â€induced cyclooxygenaseâ€2 expression in osteoarthritic cartilage. FASEB Journal, 2011, 25, 945.15.	0.5	0
112	Interleukinâ€1â€induced cyclooxygenaseâ€2 and inducible nitric oxide synthase expression in human OA chondrocytes is associated with histone H3K4 methylation. FASEB Journal, 2011, 25, 945.4.	0.5	0
113	Automatic Human Knee Cartilage Segmentation From 3-D Magnetic Resonance Images. IEEE Transactions on Biomedical Engineering, 2010, 57, 2699-2711.	4.2	98
114	Targeting subchondral bone for treating osteoarthritis: what is the evidence?. Best Practice and Research in Clinical Rheumatology, 2010, 24, 51-70.	3.3	147
115	Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI. Annals of the Rheumatic Diseases, 2010, 69, 2118-2124.	0.9	58
116	Variable Effects of 3 Different Chondroitin Sulfate Compounds on Human Osteoarthritic Cartilage/Chondrocytes: Relevance of Purity and Production Process. Journal of Rheumatology, 2010, 37, 656-664.	2.0	47
117	Meniscal extrusion predicts increases in subchondral bone marrow lesions and bone cysts and expansion of subchondral bone in osteoarthritic knees. Rheumatology, 2010, 49, 997-1004.	1.9	101
118	Effects of diacerein at the molecular level in the osteoarthritis disease process. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 95-104.	2.7	79
119	Bone marrow lesions predict site-specific cartilage defect development and volume loss: a prospective study in older adults. Arthritis Research and Therapy, 2010, 12, R222.	3.5	96
120	Fully automated system for the quantification of human osteoarthritic knee joint effusion volume using magnetic resonance imaging. Arthritis Research and Therapy, 2010, 12, R173.	3.5	35
121	Is osteoarthritis a disease involving only cartilage or other articular tissues?. Eklem Hastaliklari Ve Cerrahisi = Joint Diseases & Related Surgery, 2010, 21, 2-14.	2.5	34
122	New Perspective in Osteoarthritis: The OPG and RANKL System as a Potential Therapeutic Target?. Keio Journal of Medicine, 2009, 58, 29-40.	1.1	90
123	A single injection of anakinra for treating knee OA?. Nature Reviews Rheumatology, 2009, 5, 363-364.	8.0	16
124	Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology, 2009, 48, 1482-1490.	1.9	99
125	Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. BMC Musculoskeletal Disorders, 2009, 10, 148.	1.9	209
126	Altered mineralization of human osteoarthritic osteoblasts is attributable to abnormal type I collagen production. Arthritis and Rheumatism, 2009, 60, 1438-1450.	6.7	130

#	Article	IF	Citations
127	Treatment with ephrin B2 positively impacts the abnormal metabolism of human osteoarthritic chondrocytes. Arthritis Research and Therapy, 2009, 11, R119.	3.5	32
128	Increased expression of lipocalin-type prostaglandin D2 synthase in osteoarthritic cartilage. Arthritis Research and Therapy, 2009, 10, R146.	3.5	21
129	Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts. Bone, 2009, 44, 1143-1150.	2.9	34
130	Inhibition of interleukinâ€1Î²â€“induced matrix metalloproteinases 1 and 13 production in human osteoarthritic chondrocytes by prostaglandin D₂. Arthritis and Rheumatism, 2008, 58, 3530-3540.	6.7	53
131	Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts. Arthritis and Rheumatism, 2008, 58, 3820-3830.	6.7	51
132	Human Hip Joint Cartilage: MRI Quantitative Thickness and Volume Measurements Discriminating Acetabulum and Femoral Head. IEEE Transactions on Biomedical Engineering, 2008, 55, 2731-2740.	4.2	46
133	Cartilage in normal and osteoarthritis conditions. Best Practice and Research in Clinical Rheumatology, 2008, 22, 351-384.	3.3	424
134	Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: Influence of osteotropic factors. Bone, 2008, 43, 284-291.	2.9	55
135	Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Research and Therapy, 2007, 9, R117.	3.5	90
136	Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study. Arthritis Research and Therapy, 2007, 9, R121.	3.5	61
137	Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study. Arthritis Research and Therapy, 2007, 9, R74.	3.5	204
138	Knee meniscal extrusion in a largely non-osteoarthritic cohort: association with greater loss of cartilage volume. Arthritis Research and Therapy, 2007, 9, R21.	3.5	108
139	Extracellular localization of galectin-3 has a deleterious role in joint tissues. Arthritis Research and Therapy, 2007, 9, R20.	3.5	38
140	Meniscal tear as an osteoarthritis risk factor in a largely non-osteoarthritic cohort: a cross-sectional study. Journal of Rheumatology, 2007, 34, 776-84.	2.0	115
141	Abnormal insulin-like growth factor 1 signaling in human osteoarthritic subchondral bone osteoblasts. Arthritis Research and Therapy, 2006, 8, R177.	3.5	42
142	The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein. Arthritis Research and Therapy, 2006, 8, R181.	3.5	35
143	Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site. Arthritis Research and Therapy, 2006, 8, R26.	3.5	87
144	Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. Bone, 2006, 38, 333-341.	2.9	56

#	Article	IF	Citations
145	New thoughts on the pathophysiology of osteoarthritis: One more step toward new therapeutic targets. Current Rheumatology Reports, 2006, 8, 30-36.	4.7	34
146	Identification in human osteoarthritic chondrocytes of proteins binding to the novel regulatory site AGRE in the human matrix metalloprotease 13 proximal promoter. Arthritis and Rheumatism, 2006, 54, 2471-2480.	6.7	20
147	Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity. Journal of Rheumatology, 2006, 33, 1176-83.	2.0	16
148	Oral treatment with PD-0200347, an ?2? ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Arthritis and Rheumatism, 2005, 52, 488-500.	6.7	59
149	Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Research and Therapy, 2005, 8, R21.	3.5	205
150	The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases. Arthritis Research and Therapy, 2005, 7, R1091.	3.5	56
151	Expression and regulation of microsomal prostaglandin E synthase-1 in human osteoarthritic cartilage and chondrocytes. Journal of Rheumatology, 2005, 32, 887-95.	2.0	79
152	Ten years in the life of an enzyme: the story of the human MMP-13 (collagenase-3). Modern Rheumatology, 2004, 14, 197-204.	1.8	59
153	Activation of Peroxisome Proliferator-activated Receptor Î³ Inhibits Interleukin-1Î²-induced Membrane-associated Prostaglandin E2 Synthase-1 Expression in Human Synovial Fibroblasts by Interfering with Egr-1. Journal of Biological Chemistry, 2004, 279, 22057-22065.	3.4	100
154	Pathophysiology of osteoarthritis. Osteoarthritis and Cartilage, 2004, 12, 31-33.	1.3	207
155	New Insights into the Major Pathophysiological Processes Responsible for the Development of Osteoarthritis. Seminars in Arthritis and Rheumatism, 2004, 34, 6-8.	3.4	8
156	Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis and Rheumatism, 2004, 50, 476-487.	6.7	235
157	Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis and Rheumatism, 2004, 50, 2521-2530.	6.7	83
158	Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B4 in osteoarthritic chondrocytes: Role of transforming growth factor ? and eicosanoids. Arthritis and Rheumatism, 2004, 50, 3925-3933.	6.7	56
159	The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone, 2004, 34, 527-538.	2.9	143
160	Ten years in the life of an enzyme: the story of the human MMP-13 (collagenase-3). Modern Rheumatology, 2004, 14, 197-204.	1.8	45
161	Human Adult Chondrocytes Express Hepatocyte Growth Factor (HGF) Isoforms but Not HGF: Potential Implication of Osteoblasts on the Presence of HGF in Cartilage. Journal of Bone and Mineral Research, 2003, 18, 1073-1081.	2.8	64
162	Computer-aided method for quantification of cartilage thickness and volume changes using mri: validation study using a synthetic model. IEEE Transactions on Biomedical Engineering, 2003, 50, 978-988.	4.2	134

#	Article	IF	Citations
163	Safety and efficacy of longâ€term intraarticular steroid injections in osteoarthritis of the knee: A randomized, doubleâ€blind, placeboâ€controlled trial. Arthritis and Rheumatism, 2003, 48, 370-377.	6.7	452
164	In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis and Rheumatism, 2003, 48, 1582-1593.	6.7	112
165	Endothelin 1 promotes osteoarthritic cartilage degradation via matrix metalloprotease 1 and matrix metalloprotease 13 induction. Arthritis and Rheumatism, 2003, 48, 2855-2864.	6.7	45
166	A Novel Negative Regulatory Element in the Human Collagenase-3 Proximal Promoter Region. Biochemical and Biophysical Research Communications, 2002, 291, 1151-1159.	2.1	19
167	Study of the role of leukotriene B4 in abnormal function of human subchondral osteoarthritis osteoblasts: Effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arthritis and Rheumatism, 2002, 46, 1804-1812.	6.7	64
168	The in situ up-regulation of chondrocyte interleukin-1-converting enzyme and interleukin-18 levels in experimental osteoarthritis is mediated by nitric oxide. Arthritis and Rheumatism, 2002, 46, 2637-2647.	6.7	64
169	PPARgamma ligands as modulators of inflammatory and catabolic responses in arthritis. An overview. Journal of Rheumatology, 2002, 29, 3-14.	2.0	182
170	Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. Journal of Rheumatology, 2002, 29, 546-53.	2.0	52
171	Interleukin 17 (IL-17) induces collagenase-3 production in human osteoarthritic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1beta. Journal of Rheumatology, 2002, 29, 1262-72.	2.0	79
172	Metabolic activity of osteoblasts from periprosthetic trabecular bone in failed total hip arthroplasties and osteoarthritis as markers of osteolysis and loosening. Journal of Rheumatology, 2002, 29, 1437-45.	2.0	9
173	Metalloproteases and inhibitors in arthritic diseases. Best Practice and Research in Clinical Rheumatology, 2001, 15, 805-829.	3.3	233
174	Quantitative imaging of the structural changes of osteoarthritis: An exciting challenge for the new millennium. Current Rheumatology Reports, 2001, 3, 465-466.	4.7	3
175	Hepatocyte growth factor induction of collagenase 3 production in human osteoarthritic cartilage: Involvement of the stress-activated protein kinase/c-Jun N-terminal kinase pathway and a sensitive p38 mitogen-activated protein kinase inhibitor cascade. Arthritis and Rheumatism, 2001, 44, 73-84.	6.7	46
176	Peroxisome proliferator-activated receptor ? activators inhibit interleukin-1?-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis and Rheumatism, 2001, 44, 595-607.	6.7	196
177	In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1? synthesis. Arthritis and Rheumatism, 2001, 44, 2320-2330.	6.7	100
178	Endogenous Prostaglandin E2 and Insulin-like Growth Factor 1 Can Modulate the Levels of Parathyroid Hormone Receptor in Human Osteoarthritic Osteoblasts. Journal of Bone and Mineral Research, 2001, 16, 713-721.	2.8	59
179	Calphostin C induces AP1 synthesis and AP1-dependent c-jun transactivation in normal human chondrocytes independent of protein kinase c-? inhibition: Possible role for c-jun N-terminal kinase. Journal of Cellular Biochemistry, 2000, 76, 290-302.	2.6	15
180	Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: Possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis and Rheumatism, 2000, 43, 1290-1299.	6.7	217

#	Article	IF	Citations
181	The Induction of Cell Death in Human Osteoarthritis Chondrocytes by Nitric Oxide Is Related to the Production of Prostaglandin E2 Via the Induction of Cyclooxygenase-2. Journal of Immunology, 2000, 165, 3402-3410.	0.8	171
182	Cytokines and their role in the pathophysiology of osteoarthritis. Frontiers in Bioscience - Landmark, 1999, 4, d694.	3.0	186
183	Subchondral bone morphological and biochemical alterations in osteoarthritis. Osteoarthritis and Cartilage, 1999, 7, 321-322.	1.3	48
184	Collagenase 3 production by human osteoarthritic chondrocytes in response to growth factors and cytokines is a function of the physiologic state of the cells. Arthritis and Rheumatism, 1999, 42, 1147-1158.	6.7	82
185	Interleukin-1?-converting enzyme/caspase-1 in human osteoarthritic tissues: Localization and role in the maturation of interleukin-1? and interleukin-18. Arthritis and Rheumatism, 1999, 42, 1577-1587.	6.7	126
186	Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts. Arthritis and Rheumatism, 1999, 42, 2112-2122.	6.7	58
187	Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: Possible role in subchondral bone sclerosis. Arthritis and Rheumatism, 1998, 41, 891-899.	6.7	189
188	Transcriptional induction of cyclooxygenase-2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: Co-stimulation of AP-1 and CRE nuclear binding proteins. Journal of Cellular Biochemistry, 1998, 69, 392-413.	2.6	81
189	Transcriptional induction of cyclooxygenaseâ€2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: Coâ€stimulation of APâ€1 and CRE nuclear binding proteins. Journal of Cellular Biochemistry, 1998, 69, 392-413.	2.6	4
190	Osteoarthritis of the Knee: Report of a Task Force of the International League of Associations for Rheumatology and the Osteoarthritis Research Society. Journal of the American Geriatrics Society, 1997, 45, 850-852.	2.6	4
191	Cloning, sequencing and characterization of the 5â€²-flanking region of the human collagenase-3 gene. Biochemical Journal, 1997, 323, 13-16.	3.7	63
192	Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. Arthritis and Rheumatism, 1997, 40, 284-294.	6.7	28
193	In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis and Rheumatism, 1997, 40, 1012-1019.	6.7	353
194	Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ. In vitro mimicking effect by transforming growth factor Î². Arthritis and Rheumatism, 1997, 40, 1653-1661.	6.7	163
195	IGF and IGF-binding protein system in the synovial fluid of osteoarthritic and rheumatoid arthritic patients. Osteoarthritis and Cartilage, 1996, 4, 263-274.	1.3	63
196	Normal expression of type 1 insulin-like growth factor receptor by human osteoarthritic chondrocytes with increased expression and synthesis of insulin-like growth factor binding proteins. Arthritis and Rheumatism, 1996, 39, 968-978.	6.7	78
197	Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis and Rheumatism, 1996, 39, 1535-1544.	6.7	338
198	Increased insulin-like growth factor 1 production by human osteoarthritic chondrocytes is not dependent on growth hormone action. Arthritis and Rheumatism, 1995, 38, 413-419.	6.7	33

#	Article	IF	Citations
199	Effects of tenidap on canine experimental osteoarthritis i. morphologic and metalloprotease analysis. Arthritis and Rheumatism, 1995, 38, 1290-1303.	6.7	58
200	Interleukin-1Î² induction of tissue inhibitor of metalloproteinase (TIMP-1) is functionally antagonized by prostaglandin E2 in human synovial fibroblasts. Journal of Cellular Biochemistry, 1995, 57, 619-629.	2.6	18
201	Human Osteoarthritic Chondrocytes Possess an Increased Number of Insulin-Like Growth Factor 1 Binding Sites but are Unresponsive to its Stimulation. Arthritis and Rheumatism, 1994, 37, 253-263.	6.7	186
202	Intraarticular Injections with Methylprednisolone Acetate Reduce Osteoarthritic Lesions in Parallel with Chondrocyte Stromelysin Synthesis in Experimental Osteoarthritis. Arthritis and Rheumatism, 1994, 37, 414-423.	6.7	122
203	Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthritis and Rheumatism, 1993, 36, 1517-1527.	6.7	42
204	Expression of c-fos, c-jun,jun-B, metallothionein and metalloproteinase genes in human chondrocyte. FEBS Letters, 1992, 306, 169-172.	2.8	39
205	The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis and Rheumatism, 1992, 35, 530-540.	6.7	151
206	Immunological analysis of proteoglycan structural changes in the early stage of experimental osteoarthritic canine cartilage lesions. Journal of Orthopaedic Research, 1992, 10, 511-523.	2.3	30
207	Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs. Arthritis and Rheumatism, 1991, 34, 153-163.	6.7	156
208	Glucocorticoid Receptor Mediated Inhibition of Interleukin-1 Stimulated Neutral Metalloprotease Synthesis in Normal Human Chondrocytes*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 316-326.	3.6	77
209	Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. Arthritis and Rheumatism, 1990, 33, 1466-1476.	6.7	126
210	Human rheumatoid arthritic cartilage and its neutral proteoglycan-degrading proteases. The effects of antirheumatic drugs. Arthritis and Rheumatism, 1985, 28, 405-412.	6.7	23
211	Role of synovial membrane inflammation in cartilage matrix breakdown in the Pond-Nuki dog model of osteoarthritis. Arthritis and Rheumatism, 1985, 28, 554-561.	6.7	120
212	Cartilage degradation by neutral proteoglycanases in experimental osteoarthritis. Suppression by steroids. Arthritis and Rheumatism, 1985, 28, 1393-1401.	6.7	51
213	Ntp pyrophosphohydrolase in human chondrocalcinotic and osteoarthritic cartilage: some biochemical characteristic. Arthritis and Rheumatism, 1984, 27, 186-192.	6.7	38
214	Ntp pyrophosphohydrolase in human chondrocalcinotic and osteoarthritic cartilage: Further Studies on Histologic and Subcellular Distribution. Arthritis and Rheumatism, 1984, 27, 193-199.	6.7	56
215	Neutral proteases capable of proteoglycan digesting activity in osteoarthritic and normal human articular cartilage. Arthritis and Rheumatism, 1984, 27, 305-312.	6.7	156
216	Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis and Rheumatism, 1983, 26, 63-68.	6.7	152

#	Article	IF	Citations
217	Collagenolytic activity and collagen matrix breakdown of the articular cartilage in the pond-nuki dog model of osteoarthritis. Arthritis and Rheumatism, 1983, 26, 866-874.	6.7	124